Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910101 | 0.93 | ACACB (0.56) | L3MBTL1NPC1RAB9AHTR1BALDH1A1 | |
| SCHEMBL20172578 | 0.89 | HTR1B (0.55) | L3MBTL1MEN1KMT2AHTR1BALDH1A1 | |
| SCHEMBL12377087 | 0.86 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10895841 | 0.85 | ALDH1A1 (0.64) | L3MBTL1MEN1KMT2ANPC1HTR1B | |
| SCHEMBL2910125 | 0.85 | NQO1 (0.56) | NPC1RAB9ATAAR1SMN1; SMN2LMNA | |
| SCHEMBL10898862 | 0.84 | L3MBTL1 (0.64) | L3MBTL1MEN1KMT2ANPC1HTR1B | |
| SCHEMBL9439492 | 0.84 | TAAR1 (0.50) | L3MBTL1MEN1KMT2AHTR1BALDH1A1 | |
| SCHEMBL25806414 | 0.84 | TAAR1 (0.42) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9380548 | 0.84 | SMN1; SMN2 (0.57) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8986177 | 0.84 | LTA4H (0.56) | L3MBTL1HTR1BTAAR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| US-7985879-B2 | reacting a 5-hydroxy-4-methoxy benzoic acid derivative with N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine, to form N-methyl-N-(2-[4-hydroxyphenyl]ethyl)-5-hydroxy-4-methoxy benzene carboxamide, which is useful as an intermediate in the synthesis of lycoremine | SCINOPHARM TAIWAN LTD. (TW) | 2011-07-26 | — | — | US | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2220100-A2 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | Rheinisch-Westfälisch-Technische Hochschule Aachen (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009077462-A2 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2009-06-25 | — | — | WO | disclosed |
| US-20080255347-A1 | Process for making galantamine | SCINOPHARM TAIWAN LTD. | 2008-10-16 | — | — | US | disclosed |
| EP-0065229-B1 | BENZAZEPINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Dr. Karl Thomae GmbH (DE) | 1985-08-07 | — | — | EP | disclosed |
| US-4490369-A | HYPOTENSIVE, BRRADYCARDIAL | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0065229-A1 | Benzazepines, process for their preparation and their application as pharmaceutical preparations | Dr. Karl Thomae GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | L3MBTL1 400/4885MEN1 1469/4885KMT2A 4003/4885 |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | MAOB, MAOA, COMT | L3MBTL1 3602/4885MEN1 2296/4885KMT2A 1060/4885 |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | L3MBTL1 2473/4885MEN1 836/4885KMT2A 2121/4885 |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | L3MBTL1 259/4885MEN1 2578/4885KMT2A 3179/4885 |
| US-20080255347-A1 | Process for making galantamine | GALR2, GALE, GALR1 | L3MBTL1 3228/4885MEN1 3797/4885KMT2A 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.